celecoxib has been researched along with Carcinoma, Lobular in 3 studies
Carcinoma, Lobular: A type of BREAST CANCER where the abnormal malignant cells form in the lobules, or milk-producing glands, of the breast.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a single-centre double-blind phase II study, thirty-seven breast cancer patients were randomised to receive either pre-operative celecoxib (400 mg) twice daily for two to three weeks (n = 22) or a placebo according to the same schedule (n = 15)." | 9.17 | A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. ( Ayoubi, T; Blok, MJ; Brandão, RD; de Vries, B; Hupperets, PS; Keymeulen, K; Lindsey, P; Smeets, HJ; Tjan-Heijnen, VC; Van de Vijver, KK; van Elssen, CH; Veeck, J, 2013) |
| "Postmenopausal women with estrogen receptor (ER) and/or progesterone (PR) positive stages II-III breast cancers received 8 weeks of exemestane 25 mg daily, followed by 8 weeks of exemestane 25 mg daily and celecoxib 400 mg twice daily." | 9.15 | Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. ( Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM, 2011) |
| "In a single-centre double-blind phase II study, thirty-seven breast cancer patients were randomised to receive either pre-operative celecoxib (400 mg) twice daily for two to three weeks (n = 22) or a placebo according to the same schedule (n = 15)." | 5.17 | A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. ( Ayoubi, T; Blok, MJ; Brandão, RD; de Vries, B; Hupperets, PS; Keymeulen, K; Lindsey, P; Smeets, HJ; Tjan-Heijnen, VC; Van de Vijver, KK; van Elssen, CH; Veeck, J, 2013) |
| "Postmenopausal women with estrogen receptor (ER) and/or progesterone (PR) positive stages II-III breast cancers received 8 weeks of exemestane 25 mg daily, followed by 8 weeks of exemestane 25 mg daily and celecoxib 400 mg twice daily." | 5.15 | Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. ( Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM, 2011) |
| "CDH11 expressing basal-like breast carcinomas and other CDH11 expressing malignancies exhibit poor prognosis." | 1.40 | Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. ( Anastasiadis, PZ; Assefnia, S; Brenner, M; Brown, ML; Byers, SW; Dakshanamurthy, S; Foley, DW; Guidry Auvil, JM; Haigh, D; Hampel, C; Kallakury, B; Shapiro, L; Uren, A, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brandão, RD | 1 |
| Veeck, J | 1 |
| Van de Vijver, KK | 1 |
| Lindsey, P | 1 |
| de Vries, B | 1 |
| van Elssen, CH | 1 |
| Blok, MJ | 1 |
| Keymeulen, K | 1 |
| Ayoubi, T | 1 |
| Smeets, HJ | 1 |
| Tjan-Heijnen, VC | 1 |
| Hupperets, PS | 1 |
| Assefnia, S | 1 |
| Dakshanamurthy, S | 1 |
| Guidry Auvil, JM | 1 |
| Hampel, C | 1 |
| Anastasiadis, PZ | 1 |
| Kallakury, B | 1 |
| Uren, A | 1 |
| Foley, DW | 1 |
| Brown, ML | 1 |
| Shapiro, L | 1 |
| Brenner, M | 1 |
| Haigh, D | 1 |
| Byers, SW | 1 |
| Lustberg, MB | 1 |
| Povoski, SP | 1 |
| Zhao, W | 1 |
| Ziegler, RM | 1 |
| Sugimoto, Y | 1 |
| Ruppert, AS | 1 |
| Lehman, AM | 1 |
| Shiels, DR | 1 |
| Mrozek, E | 1 |
| Ramaswamy, B | 1 |
| Layman, RM | 1 |
| Brueggemeier, RW | 1 |
| Shapiro, CL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer[NCT01695226] | Phase 2 | 0 participants | Interventional | 2004-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for celecoxib and Carcinoma, Lobular
| Article | Year |
|---|---|
A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Celecoxib; Cyclo | 2013 |
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular | 2011 |
1 other study available for celecoxib and Carcinoma, Lobular
| Article | Year |
|---|---|
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Arthritis, Rheumatoid; Blotting, Western; Breast Neoplas | 2014 |